Can Lyme Disease Influence Alzheimer's Biomarkers? A First Live Case Study Transcript

(Transcripts are generated by AI and may contain errors)

Introduction and article announcement

Hello everyone. My name is Doctor Richard Horowitz. I am so excited to be with you today. My new article just appeared in the Journal of Alzheimer's Disease Reports.

It is entitled Improving Biomarkers of Inflammation, Including Phosphorylated Tau in a patient with Chronic Lyme Disease TLDs using Some Combination therapy, a case study, and literature review.

Alzheimer's and Lyme disease connection

The reason this article is so important is that Alzheimer's disease is now affecting 55 million people worldwide. The average risk of getting dementia as you get older is now 42% over 55 years old.

So we're in the middle of an Alzheimer's epidemic, and also a Lyme epidemic, where one out of seven people on the planet has been exposed to Lyme disease, and that we know that Medicare rates are seven times higher.

But up until now, it has only been a hypothesis that Alzheimer's disease and Lyme disease are linked. And we have now proven it for the first time in a live person where we completely reverse the Alzheimer's biomarkers, the most sensitive one, which is p tau 217 we reversed it completely with the nine week oral Dobson combination protocol.

Patient case and biomarker reversal

The other thing we proved for the first time is that all 16 factors are associated with Lyme disease. This has never been shown before. So the reason this is so important is because it has been estimated that at least one out of four people with Alzheimer's disease may be driven by Borrelia Bergdorf's by the Ancient of Lyme.

But up until now, this has only been a hypothesis. This was autopsy studies that were done by Judith McCloskey, by Eva Ciampi, by Alan MacDonald, by others who showed that there was beta amyloid and p tau.

Next, despite rickets with this neuroinflammation in the brain. But it was autopsy studies. It was never a live person. So one of my patients, who had never done combination therapy, who had elevated rheumatoid factors and also elevated Peto to 17, she agreed to do the Dobson protocol for nine weeks.

We repeated her Alzheimer's disease biomarkers three months later and they completely reversed her rheumatoid factor turned negative and the p tau 217 became normal.

Limits of anti-amyloid drugs

Now last week in the Cochrane review, they talked about the anti amyloid drugs that just were not cutting it. They were helping in some cases with the newer ones.

Lecanemab Donanemab there was slowing down the process, but nothing had stopped the process or was a good long term solution. And that's potentially because some of these cases may be due to Lyme disease.

So please go on. The Journal of Alzheimer's Disease Reports was just published today, April 27th, 2026.

Publication details and acknowledgements

And again, I just want to thank all of the researchers like Eva Shopee and Judith McCloskey and Allan Donald, all

the researchers who made this possible by providing a basis for the information that we did today, and including even Doctor Phyllis Freeman, who's published all the articles with some combination therapy.

John Fallon, I just want to thank everyone because this is a monumental time in medicine. We've just done something that has never been done before. So again, please go on the journal to see this report.

And also look at my Medical Detective Substack, which will be explaining the article in great detail. Thank you so much, and I look forward to hearing your feedback about this.

It's a really exciting time. Thank you.